Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Actinium approaches Phase 3 trial for Iomab-B
September 2015
SHARING OPTIONS:

NEW YORK—Actinium Pharmaceuticals Inc. has submitted a request for a pre-IND meeting with the U.S. Food and Drug Administration for its Iomab-B drug candidate, which is currently gearing up for a pivotal Phase 3 trial. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. Fred Hutchinson Cancer Research Center has developed BC8 to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. When labeled with radioactive isotopes, BC8 carries radioactivity to the site of cancerous growths and bone marrow. Iomab-B will be used to prepare patients for hematopoietic stem cell transplantation in a two-arm, randomized, controlled Phase 3 trial of patients with relapsed, refractory acute myeloid leukemia over the age of 55. The primary endpoint will be durable complete remission, defined as a complete remission lasting at least six months, with overall survival at one year as the secondary endpoint.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.